Notes to the consolidated financial statements 7 Auditors remuneration During the year the Group including its overseas subsidiaries obtained the following services from the Companys auditors as detailed below: Year to 31 March 2007 2006 m m Fees payable to the Companys auditors for the audit of the Companys annual financial statements 0.6 0.6 Fees payable to the Companys auditors and its associates for other services: the audit of the Companys subsidiaries, pursuant to legislation 1.5 1.4 Total audit fees 2.1 2.0 Other services pursuant to legislation 0.1 Other services relating to taxation 0.1 All other services 0.1 0.1 2.3 2.2 In addition to the above, fees totalling 0.1 million 2006 0.1 million were paid to the Companys auditors in respect of the audit of Group pension schemes.
8 Exceptional items Exceptional items are as follows: Year to 31 March 2007 2006 m m Continuing Impairment and closure costs a 33 272 Deferred payment provision release b 20 US healthcare benefit curtailment c 24 13 248 Discontinued Eastern Sugar d 23 10 248 a Impairment and closure costs of 33 million have been recognised in 2007 following a fundamental review of the manufacturing activities at the Selby, UK, factory for citric acid and astaxanthin.
Both of these activities continued to be loss making in the year to 31 March 2007.
The exceptional loss includes costs of closure of the citric acid line following the decision to cease production and the write down of goodwill and other assets relating to the astaxanthin business.
These businesses are both reported within the Food & Industrial Ingredients, Americas division.
The impairment losses recognised in 2006 comprised two items: a 263 million impairment of property, plant and equipment in Food & Industrial Ingredients, Europe arising from the expected impact of the new EU sugar regime regulations and a 9 million impairment of property, plant and equipment in the UK citric acid business.
b The deferred payment provision credit of 20 million relates to the Sucralose business.
As part of the realignment of Sucralose activities with McNeil Nutritionals, LLC McNeil in April 2004 a provision was set up for deferred consideration payable to McNeil based on the growth in sales of SPLENDA Sucralose by Tate & Lyle over a period of five years to March 2009.
It is anticipated that the provision will not now be fully utilised and consequently 20 million has been released to the income statement in the year.
c An exceptional credit of 24 million arose in 2006 from a change in benefits provided to certain members of the Groups US Healthcare Scheme following changes to US Government healthcare provisions.
d Exceptional items in discontinued operations of 23 million relate to the Groups Eastern Sugar joint venture.
These comprise a 14 million net gain expected on termination of operations following surrender of sugar quota to the EU Restructuring Fund under the terms of the EU sugar regime and a 9 million gain following a favourable outcome to a long-running litigation dispute with the government of the Czech Republic.
The tax impact on continuing net exceptional items was a 3 million charge 2006 19 million credit and on total net exceptional items was a 7 million charge 2006 19 million credit.
Tax credits on exceptional items are only recognised to the extent that losses created are expected to be recoverable in the future.
In addition a further 18 million exceptional tax charge was recognised in the year to 31 March 2007 2006 nil of which 13 million related to an adjustment to the tax credit recognised on the impairment in Food & Industrial Ingredients, Europe in the year ended 31 March 2006.
The balance of 5 million relates to a one-off charge relating to discontinued operations.
Exceptional items include nil million 2006 1 million attributable to minority interests.
